The EchoCRT trial is designed to demonstrate that optimal medical therapy plus CRT reduces all-cause mortality or first hospitalisation for worsening heart failure in the study population compared to optimal medical therapy alone. Eligible patients must have echocardiographic evidence of left ventricular dyssynchrony (discoordinated pumping action of the heart) with a

«« Agfa HealthCare signs IMPAX


Medis and TomTec Launch Joint Cardiac Imaging and Analysis Product »»


Latest Articles

The EchoCRT trial is designed to demonstrate that optimal medical therapy plus CRT reduces all-cause mortality or first hospitalisation for worsening hea...